Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avadel Pharmaceuticals plc filings document the formal record of a completed corporate-status transition, including Nasdaq removal of its ordinary shares on Form 25 and a Form 15 notice covering termination or suspension of Exchange Act reporting obligations after the acquisition by Alkermes plc.
Earlier filings include Form 8-K material-event reports on material agreements, termination of an at-the-market offering agreement, shareholder voting matters, capital-structure disclosure, Regulation FD clinical disclosures for LUMRYZ and REVITALYZ, governance matters, risk factors and operating and financial results.
The Vanguard Group has filed a Schedule 13G disclosing a 5,564,259-share beneficial ownership position in Avadel Pharmaceuticals plc (AVDL), representing 5.74 % of the outstanding common stock as of 30 June 2025. The position is being reported on a passive basis under Rule 13d-1(b) and classified as an investment adviser (IA).
Voting rights are limited: Vanguard reports 0 shares with sole voting power and 107,614 shares with shared voting power. Dispositive authority is larger, with 5,361,014 shares under sole dispositive power and 203,245 shares under shared dispositive power, indicating the firm can direct disposition of virtually the entire stake while exercising minimal influence over corporate governance.
The filing, signed by Head of Global Fund Administration Ashley Grim on 29 July 2025, confirms that the shares were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.
Avadel Pharmaceuticals (Nasdaq: AVDL) filed an 8-K disclosing a decisive legal outcome.
On June 27 2025, the U.S. Court of Appeals for the D.C. Circuit issued a unanimous ruling affirming the District Court’s October 30 2024 judgment that upheld the FDA’s approval of LUMRYZ. The appeal was brought by Jazz Pharmaceuticals, which had alleged the approval violated the Administrative Procedure Act. With the appeal dismissed, LUMRYZ’s approval stands, eliminating a significant regulatory and litigation overhang.
No further conditions, penalties, or operational changes were reported.